Kidney Transplant Rejection Market Outlook For 2026–2030 Covering Growth Drivers And Industry Trends

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Kidney Transplant Rejection Market Projected To Reach By 2030?

The market size for kidney transplant rejection has seen substantial growth recently. It is projected to expand from $3.51 billion in 2025 to $3.76 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historical period is attributable to an increase in kidney transplant procedures, advancements in histopathological assessment techniques, the broader availability of immunosuppressive drugs, the expansion of transplant center networks, and improved post-transplant patient survival rates.

The kidney transplant rejection market size is expected to experience strong growth in the coming years. It is projected to expand to $5.01 billion in 2030, at a compound annual growth rate (CAGR) of 7.4%. This growth during the forecast period can be attributed to rising demand for personalized immunosuppression strategies, increasing adoption of molecular diagnostics, the expansion of precision medicine in transplant care, a growing focus on long-term graft survival, and increasing investment in transplant monitoring technologies. Major trends anticipated in the forecast period include the increasing uptake of biomarker-based rejection monitoring, a rising use of genomics-based diagnostic approaches, the growing optimization of immunosuppressive therapy protocols, the expansion of non-invasive rejection surveillance methods, and an enhanced focus on the early detection of chronic rejection.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33190&type=smp

What Key Factors Are Shaping The Kidney Transplant Rejection Market Landscape?

The increasing occurrence of end-stage renal disease is anticipated to drive expansion in the kidney transplant rejection market moving ahead. End-stage renal disease (ESRD) signifies the ultimate, irreversible phase of chronic kidney disease where kidneys cannot perform sufficiently without either dialysis or a kidney transplant. The frequency of end-stage renal disease is increasing because of the growing prevalence of chronic conditions such as diabetes and hypertension, ailments that gradually harm the kidneys and result in kidney failure. Rejection of kidney transplants necessitates advanced monitoring and therapeutic measures, thereby directly assisting in the management of end-stage renal disease by ensuring transplanted kidneys stay functional and patients preserve their kidney health. As an illustration, data from September 2024, provided by the National Institute of Diabetes and Digestive and Kidney Diseases, a US-based government institute, indicated that in 2023, over 808,000 individuals in the United States were coping with end-stage kidney disease (ESKD), also referred to as end-stage renal disease (ESRD). Of these, 68% were undergoing dialysis, and 32% had received a kidney transplant. Consequently, the escalating incidence of end-stage renal disease is fueling the expansion of the kidney transplant rejection market.

How Is The Kidney Transplant Rejection Market Categorized Across Its Segment Groups?

The kidney transplant rejection market covered in this report is segmented –

1) By Rejection Type: Chronic Rejection; Acute Rejection

2) By Treatment: Immunosuppressive Drugs; Antibody-Mediated Rejection Therapies

3) By Diagnostic Approach: Biomarker-Based Diagnostics; Genomics-Based Diagnostics

4) By Therapeutics: Small Molecule Inhibitors; Biologic Therapies

5) By End-Users: Transplant Centers Or Hospitals; Diagnostic Laboratories; Pharmacies

Subsegments:

1) By Chronic Rejection: Antibody Mediated Chronic Rejection; Chronic Allograft Nephropathy; Interstitial Fibrosis And Tubular Atrophy; Vascular Chronic Rejection; Mixed Chronic Rejection

2) By Acute Rejection: Cellular Acute Rejection; Antibody Mediated Acute Rejection; Hyperacute Rejection; Mixed Acute Rejection; Vascular Acute Rejection

What Market Trends Are Affecting The Kidney Transplant Rejection Market?

Major companies operating in the kidney transplant rejection market are concentrating on creating advanced diagnostic methods, such as noninvasive urinary biomarker testing, to facilitate quicker, safer, and more precise identification of transplant rejection. This noninvasive approach involves examining urine samples to pinpoint molecular markers linked to kidney inflammation or rejection, thereby assisting medical professionals in promptly and safely diagnosing transplant complications, bypassing the necessity for invasive biopsies. As an illustration, in May 2024, Thermo Fisher Scientific Inc., a US-based biotechnology firm, introduced its CXCL10 testing service, representing an innovative diagnostic instrument designed for individuals who have undergone kidney transplantation. The CXCL10 test specifically identifies the CXCL10 chemokine within urine, a marker known to be associated with early stages of transplant rejection and inflammation. This test provides results within 24 hours, facilitating faster clinical judgments, minimizing the requirement for superfluous biopsies, and enhancing patient comfort through its noninvasive sample collection method. Developed and verified by Thermo Fisher’s One Lambda Laboratories, this assay offers a combination of high sensitivity, specificity, and user-friendliness in clinical environments, thereby contributing to enhanced post-transplant care and improved patient outcomes.

Which Firms Are Influencing Competition In The Kidney Transplant Rejection Market?

Major companies operating in the kidney transplant rejection market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., ChugAI Pharmaceutical Co. Ltd., Eurofins Scientific SE, Illumina Inc., Natera Inc., CareDx Inc., Azurity Pharmaceuticals Inc., Insight Molecular Diagnostics, and RenalytixAI plc.

Get The Full Kidney Transplant Rejection Market Report:

https://www.thebusinessresearchcompany.com/report/kidney-transplant-rejection-market-report

Which Region Accounts For The Largest Portion Of The Kidney Transplant Rejection Market?

North America was the largest region in the kidney transplant rejection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney transplant rejection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Kidney Transplant Rejection Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=33190&type=smp

Browse Through More Reports Similar to the Global Kidney Transplant Rejection Market 2026, By The Business Research Company

Kidney Transplant Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-transplant-global-market-report

Organ Transplant Immunosuppressant Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/organ-transplant-immunosuppressant-drugs-global-market-report

Continuous Renal Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/continuous-renal-replacement-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795